AKINow Mission
To promote excellence in the prevention and treatment of Acute Kidney Injury (AKI) by building a foundational program that transforms the delivery of AKI care, reduces morbidity and mortality and improves long-term outcomes.
AKINow’s Focus Areas
AKINow Spotlight
Roadmap for AKI-D Outpatient Care ASN Kidney Health Guidance in JASN
Now available in JASN, the ASN Kidney Health Guidance on the Outpatient Management of Patients with Dialysis-Requiring Acute Kidney Injury provides nephrologists and kidney health professionals with evidence-based strategies to:
- Identify improvements in kidney function early to optimize recovery and potential dialysis liberation.
- Implement individualized care plans distinct from long-term dialysis protocols.
- Coordinate efforts between patients, caregivers, and various health care personnel for best practices in AKI-D management.Empower your practice with expert insights to enhance improvement in kidney function and to deliver care that optimizes chances of recovery.
Empower your practice with expert insights to enhance improvement in kidney function and to deliver care that optimizes chances of recovery.
Acute Kidney Injury: From Bench to Bedside May 4-7, 2025 | Lansdowne Resort, Leesburg, VA
This 3rd conference has a theme of “Artificial Intelligence in AKI Research” and brings together basic, translational, and clinical researchers with industry partners in an informal and interactive setting to present unpublished, high-impact studies related to AKI.
AKINow Journal Club: Intravenous Amino Acids for Kidney Protection Recorded on Dec. 5, 2024
Acute kidney injury (AKI) is a serious and common complication of cardiac surgery. Intravenous amino acids increase kidney perfusion and recruit renal functional reserve. However, the efficacy of amino acids in reducing the occurrence of AKI after cardiac surgery is uncertain. In a multinational, double-blind trial, the authors randomly assigned adult patients who were scheduled to undergo cardiac surgery with cardiopulmonary bypass to receive an intravenous infusion of either a balanced mixture of amino acids or placebo for up to 3 days.
View this Journal Club Presentation to learn the outcome of this research.
AKINow Resource Library
Automated medication-targeted alerts on AKI outcomes (AKINow Journal Club Presentation) Recorded July 20, 2023
In this randomized control trial, the authors investigated whether an automated clinical decision support system affects discontinuation rates of potentially nephrotoxic medications and improves outcomes in patients with AKI.
The paper’s lead author, Dr. F. Perry Wilson, discusses the study and answers questions.
Nat Commun 14, 2826 (2023). https://doi.org/10.1038/s41467-023-38532-3 Published May 17, 2023
Watch Inaugural AKINow Journal Club from February 7, 2023
Authors Kensei Taguchi and Craig Brooks discuss the role of CG1 and CDK5 in maladaptive repair. Amandeep Bajwa moderates.
